GAIN THERAPEUTICS, INC Operating Lease, Right-of-Use Asset, Amortization Expense
GAIN THERAPEUTICS, INC (GANX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $130.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2021-11-12
- GAIN THERAPEUTICS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2021-09-30 was $50.13K, a 81.62% increase year-over-year.
- GAIN THERAPEUTICS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2021-06-30 was $42.57K, a 77.13% increase year-over-year.
- GAIN THERAPEUTICS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2021-03-31 was $37.30K, a 53.85% increase year-over-year.
- GAIN THERAPEUTICS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2020-09-30 was $27.60K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|---|---|
| 2021-09-30 | $50.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $92.69K derived: sum of 2 quarters · filed 2021-11-12 | $130.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $42.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $79.87K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $37.30K 10-Q · filed 2021-05-10 | ||
| 2020-09-30 | $27.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $51.63K derived: sum of 2 quarters · filed 2021-11-12 | $75.88K 10-Q · filed 2021-11-12 |
| 2020-06-30 | $24.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $48.28K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $24.24K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |